V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Twist Bioscience Executive Compensation (FY25)

TWST · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Emily Leproust
Latest say-on-pay support
=
February 6, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Twist Bioscience brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): February 6, 2026
8 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Twist Bioscience brief$1,500Get the executive brief
Velarion Member, one year
317 figures on this page: 312 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Emily Leproust: $7,620,611 → $13,781,570 (80.8% higher)
CEO pay ratio: 68:1 → 73.2:1 (7.6% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Twist Bioscience's chief executive and what were they paid?
Emily Leproust was paid $13,781,570 in total compensation as Chief Executive Officer and Chair of the Board for fiscal 2025. Compared with the $7,620,611 reported for fiscal 2024, Leproust's total was 80.8% higher.
What was Twist Bioscience's say-on-pay result?
The say-on-pay proposal drew 76.4% support at the meeting held February 6, 2026 for fiscal 2025.
Which companies are in Twist Bioscience's peer group?
The disclosed peer group includes 10x Genomics, Inc., Azenta, Inc., BioLife Solutions, Inc., CareDx, Inc. and Cytek Biosciences, Inc., among others.
What is Twist Bioscience's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 73.2:1, against median employee compensation of $188,208.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Emily Leproust
Chief Executive Officer and Chair of the Board
◇—◇—◇—◇◇
James Thorburn
Chief Financial Officer
◇—◇—◇—◇◇
Patrick Finn
President and Chief Operating Officer
◇—◇—◇—◇◇
William Banyai
Senior Vice President of Advanced Development and General Manager of Data Storage
◇—◇—◇—◇◇
Patrick Consultant
Former Chief Operating Officer
Departed during or after this year
◇—◇———◇◇
Dennis Cho
Senior Vice President, General Counsel, Secretary and Chief Ethics and Compliance Officer
◇—◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Emily Leproust
Chief Executive Officer and Chair of the Board
◇◇◇—◇—◇◇
Patrick Finn
President and Chief Operating Officer
◇◇◇—◇—◇◇
Paula Green
Senior Vice President of Human Resources
◇◇◇—◇—◇◇
Dennis Cho
Chief Legal Officer and Corporate Secretary
◇◇◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Emily Leproust
Chief Executive Officer and Chair of the Board
◇—◇—◇—◇◇
Adam Laponis
Chief Financial Officer
◇◇◇—◇—◇◇
Patrick Finn
President and Chief Operating Officer
◇—◇—◇—◇◇
William Banyai
Senior Vice President of Advanced Development and General Manager of Data Storage
◇—◇—◇—◇◇
Paula Green
Senior Vice President of Human Resources
◇—◇—◇—◇◇
Dennis Cho
Chief Legal Officer and Corporate Secretary
◇—◇—◇—◇◇
James Thorburn
Former Chief Financial Officer
Departed during or after this year
◇—◇———◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Emily Leproust
Chief Executive Officer and Chair of the Board
◇—◇—◇—◇◇
Patrick Finn
President and Chief Operating Officer
◇—◇—◇—◇◇
Adam Laponis
Chief Financial Officer
◇—◇—◇—◇◇
Dennis Cho
Chief Legal Officer and Corporate Secretary
◇—◇—◇—◇◇
Paula Green
Senior Vice President of Human Resources
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Adam LaponisRSU◇——◇——◇
Adam LaponisPSU◇◇◇—◇—◇
Dennis ChoPSU◇◇◇—◇—◇
Dennis ChoRSU◇——◇——◇
Emily M. LeproustPSU◇◇◇—◇—◇
Emily M. LeproustRSU◇——◇——◇
Patrick FinnPSU◇◇◇—◇—◇
Patrick FinnRSU◇——◇——◇
Paula GreenRSU◇——◇——◇
Paula GreenPSU◇◇◇—◇—◇
Fiscal 2022, 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Dennis ChoPSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Patrick FinnPSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Paula GreenPSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Emily LeproustPSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Adam LaponisPSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Adam Laponis
Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Change-in-control base◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Dennis Cho
Chief Legal Officer and Corporate Secretary · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Patrick Finn
President and Chief Operating Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Paula Green
Senior Vice President of Human Resources · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Change-in-control base◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Trynka Shineman Blake
◇◇————◇
Robert Chess
Lead independent director
◇◇————◇
Jan Johannessen
◇◇————◇
Nelson C. Chan
◇◇————◇
Robert Ragusa
◇◇————◇
Melissa A. Starovasnik
◇◇————◇
Keith Crandell
◇◇————◇
Xiaoying Mai
◇————◇◇
Emily M. Leproust served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Stock ownership guideline: Executive and director stock ownership guidelines which align Board and executive interests with the long-term interests of stockholders.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 10x Genomics, Inc. TXG
  • Azenta, Inc. AZTA
  • BioLife Solutions, Inc. BLFS
  • CareDx, Inc. CDNA
  • Cytek Biosciences, Inc. CTKB
  • Guardant Health, Inc. GH
  • Insmed Incorporated INSM
  • Maravai LifeSciences Holdings, Inc. MRVI
  • Natera, Inc. NTRA
  • NeoGenomics, Inc. NEO
  • NovoCure Limited NVCR
  • Pacific Biosciences of California, Inc. PACB
  • Quanterix Corporation QTRX
  • REGENXBIO Inc. RGNX
  • Schrödinger, Inc. SDGR
  • Ultragenyx Pharmaceutical Inc. RARE
  • Veracyte, Inc. VCYT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025February 6, 2026=◇◇◇
2024February 5, 2025=◇◇◇
2023February 6, 2024=◇◇◇
2022February 7, 2023=◇◇◇
2021February 8, 2022=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Emily Leproust (Chief Executive Officer and Chair of the Board), FY2025 total compensation $13,781,570 (base salary $720,000) [exec_comp, SEC accession 0001581280-26-000006, filed 2026-01-06]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Twist Bioscience files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Twist Bioscience disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Twist Bioscience sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Twist Bioscience's disclosed peer group is defensible, who names Twist Bioscience back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
317 figures on this page: 312 cited to the filing that reported them, 5 calculated from figures it prints.
312 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001581280-26-000022
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001581280-26-000006
    Compensation Discussion and Analysis · Director Compensation · Grants of Plan-Based Awards in Fiscal Year · Outstanding equity awards as of · and 2 more sections
  3. 0001104659-25-011543
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001628280-25-000641
    Summary Compensation Table
  5. 0001104659-24-011607
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001104659-23-014513
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001104659-23-001907
  8. 0001104659-22-015913
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Twist Bioscience executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/TWST (accessed 2026).
Short form: data: Velarion

The Twist Bioscience brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Twist Bioscience and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Twist Bioscience discloses

The companies named in TWST's own disclosed peer group.

10x Genomics, Inc.Azenta, Inc.BioLife Solutions, Inc.CareDx, Inc.Cytek Biosciences, Inc.Guardant Health, Inc.Insmed IncorporatedMaravai LifeSciences Holdings, Inc.Natera, Inc.NeoGenomics, Inc.NovoCure LimitedPacific Biosciences of California, Inc.Quanterix CorporationREGENXBIO Inc.Schrödinger, Inc.Ultragenyx Pharmaceutical Inc.Veracyte, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy